Form 4: aTyr Pharma Director Sara Zaknoen Acquires 50,000 Stock Options

Director Sara Zaknoen acquired 50,000 stock options in aTyr Pharma on May 1, 2025, according to a Form 4 filing.

Summary

• Sara Zaknoen, a director of aTyr Pharma, acquired 50,000 stock options on May 1, 2025.
• The options have an exercise price of $3.34.
• The options vest fully on the earlier of May 1, 2026, or the Issuer's 2026 Annual Meeting of Stockholders, contingent on continued service on the Board of Directors.
• The options expire on May 1, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating an insider transaction. The acquisition of options can be seen as a positive sign of confidence, but it's not a strong indicator.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is tied to the director's continued service and the company's annual meeting in 2026.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

aTyr Pharma, Sara Zaknoen, stock options, Form 4, director, acquisition, beneficial ownership